Soleno Therapeutics Inc SLNO
We take great care to ensure that the data presented and summarized in this overview for SOLENO THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SLNO
View allLatest Institutional Activity in SLNO
Top Purchases
Top Sells
About SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Insider Transactions at SLNO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 29
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,870
-2.58%
|
$322,890
$47.5 P/Share
|
|
Aug 29
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
5,435
-3.05%
|
$255,445
$47.5 P/Share
|
|
Aug 29
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
58,391
-3.69%
|
$2,744,377
$47.5 P/Share
|
|
Aug 29
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
5,435
-2.33%
|
$255,445
$47.5 P/Share
|
|
Aug 29
2024
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-1.56%
|
$4,700,000
$47.22 P/Share
|
|
Aug 28
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,661
-2.39%
|
$313,067
$47.61 P/Share
|
|
Aug 28
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
5,270
-2.8%
|
$247,690
$47.61 P/Share
|
|
Aug 28
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
56,613
-3.36%
|
$2,660,811
$47.61 P/Share
|
|
Aug 28
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
5,270
-2.17%
|
$247,690
$47.61 P/Share
|
|
Aug 28
2024
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
425,000
-6.23%
|
$19,975,000
$47.35 P/Share
|
|
Aug 27
2024
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
500,000
-6.83%
|
$24,000,000
$48.73 P/Share
|
|
Aug 15
2024
|
Dawn Carter Bir |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+50.0%
|
-
|
|
Aug 06
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
69,131
-2.54%
|
$3,041,764
$44.93 P/Share
|
|
Aug 06
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
5,977
-1.57%
|
$262,988
$44.93 P/Share
|
|
Aug 06
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,134
-1.85%
|
$357,896
$44.93 P/Share
|
|
Aug 06
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
5,957
-1.99%
|
$262,108
$44.93 P/Share
|
|
Aug 05
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
58,213
-3.0%
|
$2,619,585
$45.81 P/Share
|
|
Aug 05
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
5,032
-1.9%
|
$226,440
$45.81 P/Share
|
|
Aug 05
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,849
-2.22%
|
$308,205
$45.81 P/Share
|
|
Aug 05
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
5,017
-2.39%
|
$225,765
$45.81 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 867K shares |
|---|---|
| Conversion of derivative security | 330K shares |
| Grant, award, or other acquisition | 1.49M shares |
| Exercise of conversion of derivative security | 50.9K shares |
| Exercise of in-the-money or at-the-money derivatives securities | 8.48M shares |
| Open market or private sale | 2.79M shares |
|---|---|
| Bona fide gift | 12.2K shares |